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The effects of metabolic acidosis on hone formation and bone resorption
in the rat. Metabolic acidosis (MA) has been implicated in the patho-
genesis of both osteomalacia and osteopenia. Alterations in the secre-
tion of parathyroid hormone and in the metabolism of vitamin D may
contribute to such skeletal changes. To minimize the influence of these
factors, quantitative bone histology and measurements of bone forma-
tion using double tetracycline labeling were done in thyroparathyroid-
ectomized (TPTX) rats with MA induced by ammonium chloride
(TPTX-A), and in both non-acidotie TPTX (TPTX-C) and intact (C)
controls. To evaluate the response of both cortical and trabecular bone
to MA, histologic studies were done at three separate sites in the tibia,
cortical bone from the mid-shaft, and trabeeular bone from the
epiphysis and from the metaphysis. Plasma pH was lower in TPTX-A,
7.24 0.10, than in either TPTX-C, 7.39 0.03, or C, 7.43 0.04, P
<0.01, and urinary hydroxyproline excretion increased from 89.8 8.7
in TPTX-C to 150.2 25.9 pg/mg/ereatinine in TPTX-A, P < 0.01.
Resorption surface at the epiphysis increased from 1.8 0.6% in
TPTX-C to 4.0 1.6% in TPTX-A, P < 0.05, values not different from
those in C, 3.1 1.1%. Resorption surface was unchanged at other
skeletal sites, but total bone volume at the metaphysis fell from 15.5
5.6% in TPTX-C to 9.0 4.3% in TPTX-A, P < 0.05. Bone formation
was reduced at each skeletal site in TPTX-A vs. TPTX-C, P < 0.05 for
all values, but histologic evidence of osteomalacia was not observed.
Thus, bone resorption is enhanced and bone formation is impaired in
MA. Both changes may contribute to osteopenia, but osteomalaeia is
not a direct consequence of MA.
Metabolic acidosis is associated with an increase in the
urinary excretion of calcium and with negative skeletal calcium
balance both in man and in experimental animals [1—3]. These
changes may result in the development of osteopenia [41. It has
been suggested that calcium is mobilized from the skeleton in
metabolic acidosis either through the dissolution of bone min-
eral directly [5—7] or by the stimulation of cell—mediated bone
resorption [8, 9]. Several investigators have reported evidence
of enhanced cell—mediated bone resorption in morphologic
studies of bone in acidptic rats [4, 91. Osteopenia can also
develop due to disturbances in the accretion of mineral into
bone [101. Such changes may occur as a consequence of either
reductions in the rate of bone formation or defects in the
mineraiization of osteoid [10]. The latter disturbance leads to
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the development of osteomalacia, and this disorder has been
more commonly described in humans with metabolic acidosis
[11—13]. However, neither of these two pathogenic factors for
osteopenia has been evaluated using the technique of double
tetracycline labeling of bone.
The current studies were designed to examine the histologic
and dynamic response of bone to metabolic acidosis. Quantita-
tive histology and double tetracycline labeling of bone were
done in thyroparathyroidectomizcd (TPTX) rats with metabolic
acidosis induced by ammonium chloride feeding and in pair—fed
TPTX controls. Thyroparathyroidectomized rats were studied
to minimize the possible influence of changes in the serum
levels of parathyroid hormone (PTH) and 1,25 dihydroxyvi-
tamin D on bone growth and bone histology. Also, because of
evidence that the skeletal response to several hormonal and
chemical stimuli may differ as a function of the type of bone and
the skeletal site evaluated [14—16], specimens of bone from
three separate areas of the skeleton were examined in all
animals.
The results indicate that metabolic acidosis is associated with
reductions in the formation of mineralized bone at all skeletal
sites evaluated. Histologic evidence of increased bone resorp-
tion was also documented at selected sites within the skeleton.
Both changes may contribute to the pathogenesis of osteopenia
in metabolic acidosis. Finally, although osteomalacia has been
noted in clinical studies of metabolic acidosis, histologic evi-
dence of defective mineralization was not apparent in the
current investigation. These observations in TPTX rats suggest
that osteomalacia is not a direct consequence of metabolic
acidosis.
Methods
Experimental protocol—Experiment #1
Weanling male Holtzman rats (Holtzman Co., Madison,
Wisconsin, USA) were obtained at three weeks of age and
underwent thyroparathyroidectomy (TPTX) five days before
study. TPTX was achieved by blunt dissection under light ether
anesthesia. The adequacy of TPTX was confirmed by measure-
ments of serum calcium concentrations 48 hours after surgery;
a decrement in the serum calcium concentration of 2 mg/dl or
greater from pre-operative levels was taken as evidence of
successful extirpation of the parathyroid glands. TPTX animals
were given daily subcutaneous injections of thyroxine, 0.1
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tg/100 g body weight, beginning on the second day after
surgery, and these were continued until completion of the
study.
Thyroparathyroidectomized rats were randomly assigned to
either a control (TPTX-C, N = 12) or an acidotic (TPTX-A, N
= 10) group. All rats were housed in individual suspended wire
cages with free access to water and maintained on a low
hydroxyproline diet that contained 0.6% calcium, 0.35% phos-
phorus, and 10 IU of vitamin D/l00 grams of chow for the
duration of study. Animals in TPTX-A were given a solution of
1.8% ammonium chloride as the drinking water; rats in TPTX-C
received distilled water only for drinking. To maintain similar
rates of weight gain for each study group, animals in TPTX-C
were pair—fed with rats in TPTX-A.
All animals were given single intraperitoneal injections of
tetracycline HC1, 20 mg/kg, on the first day of study and again
24 hours before killing on day 14 at the end of the experiment
[17]. On each of the final three days of study, 24 hour collec-
tions of urine were obtained, and aliquots of urine were saved
for subsequent analysis. The rats were killed on day 14 by
exsanguination from the abdominal aorta while under pentobar-
bital anesthesia, 40 mg/kg. Whole blood was collected under
anaerobic conditions and temporarily kept on ice until blood gas
measurements were completed; arterial pH and arterial pCO2
were determined using a microblood gas analyser (Instrumen-
tation Laboratories, Model 213, Lexington, Massachusetts,
USA). Plasma bicarbonate concentrations were calculated us-
ing the Henderson—Hasselbalch equation with a pK of 6.1 and a
solubility coefficient of 0.0301. Samples of plasma were also
frozen for subsequent biochemical measurements.
After the animals were killed, the right tibia was removed,
stripped of adhering soft tissue, and placed in gauze saturated
with 10% formalin until tissue sections were prepared. Quanti-
tative bone histology and measurements of bone formation
were done for both TPTX-C and TPTX-A as described previ-
ously from this laboratory [17].
Experimental protocol—Experiment #2
For Experiment #1, the excretion of hydroxyproline in the
urine increased from control values in TPTX-A (see Results); in
contrast, bone resorption at the tibial cortex did not increase by
histologic criteria in acidotic animals. Thus, the histologic
findings in cortical bone failed to confirm the biochemical
evidence of enhanced bone resorption in acidotic animals.
However, changes in bone resorption may have occurred at
skeletal sites not examined in this experiment. Therefore, a
second study was done in TPTX rats to evaluate the histologic
and dynamic responses of bone to metabolic acidosis at addi-
tional sites within the skeleton as well as in the tibia! cortex.
Histologic studies were done on sections of bone taken from
three different sites within the tibia, two that undergo primary
modeling, that is, cortical bone at the tibia! diaphysis and
trabecular bone at the proximal tibial metaphysis, and one that
undergoes secondary remodeling, that is, trabecular bone at the
epiphysis of the proximal tibia. The site in cortical bone
evaluated in Experiment #2 was the same as that for Experi-
ment #1.
As in Experiment #1, animals in TPTX-C (N = 9) and
TPTX-A (N = 8) were given either water or ammonium
chloride. To control for changes in bone formation and resorp-
tion that occur with thyroparathyroidectomy alone, non-
acidotic animals with intact parathyroid glands (C, N = 10)
were also studied, and these animals served as a second intact
control group. Animals in C underwent sham TPTX. As for
Experiment #1, C and TPTX-C rats were pair—fed with animals
in TPTX-A. On the final three days of Experiment #2,
twenty—four hour collections of urine were made and aliquots
were saved for subsequent biochemical determinations.
Cortical bone measurements—Experiments #1 and #2
Thirty—five sm sections of non-decalcified cortical bone were
obtained from the tibia! diaphysis at the fibular junction as
previously described [17]. These were hand ground to a thick-
ness of 10 to 15 microns, stained with nuclear fast red, and
examined by both light and fluorescence microscopy [17].
Trabecular bone measurements—Experiment #2
Sections of undecalcified trabecular bone from both the
metaphysis and the epiphysis of the proximal tibia were pre-
pared from plastic embedded specimens of the proximal tibia
[16, 18, 19]. Five m sections were stained using the modified
Goldner technique and examined by light microscopy [16, 18];
ten m sections were mounted unstained in 10% glycerol and
viewed by fluorescence microscopy for the evaluation of tetra-
cycline labels [16, 18].
Quantitative histological measurements were done using a
digitizer interfaced with a microcomputer [16—18]. All measure-
ments of length, width, and area for cortical and trabecular
bone were determined directly from projected images using a
projection prism and drawing tube attached to a Leitz micro-
scope (Leitz, Wetzlar, FRG) [16—18].
Quantitative histology of trabecular bone was done at the
epiphysis and at the metaphysis by methods described previ-
ously [16, 18]. For metaphyseal bone, an area within the
secondary spongiosa measuring 1.8 mm x 0.6 mm was evalu-
ated; this site consists predominantly of fully calcified trabecu-
lae extending into the marrow space [16]. The histologic eval-
uation of cortical bone from the tibial diaphysis was completed
as described in detail elsewhere [17, 20]; these results represent
measurements obtained at both the periosteal and endosteal
surfaces of cortical bone.
The following histologic variables were determined for all
three skeletal sites: 1) total bone area (%)—the area of bone,
including both mineralized bone and osteoid, expressed as a
percentage of the total tissue area; 2) osteoid area (%)—the area
of osteoid expressed as a percentage of the total bone area; 3)
osteoid seam width (m)—the mean width of osteoid seams; 4)
forming surface (%)—the percentage of bone surfaces covered
by osteoid seams; 5) resorption surface (%)—the percentage of
bone surfaces characterized by the presence of scalloped bone
resorptive lacunae; and 6) tetracycline labeled surface (%)—the
percentage of the total bone surface that exhibited double bands
of tetracycline fluorescence [16—18].
The methods for the calculation of the rates of bone forma-
tion and bone apposition in the tibia! cortex of the rat and the
verification of these techniques have been presented in detail
elsewhere [17, 20]. For trabecular bone, the rate of apposition
of mineralized bone at the tibial epiphysis was determined from
measurements of the width of separation of double tetracycline
labels divided by the time interval between the administration
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Table 1. Serum and urine biochemjstries in cnntrol (C), thyroparathyroidectomized control (TPTX-C) and thyroparathyroidectomized acidotic
(TPTX-A) ratsa
TPTX-CN 12
Plasma pH 7.40
Plasma [1-1+] 39.8
nEqI/iter 3.3
Plasma HCO3 23.6
mEq/liter 2.7
Plasma calcium 5.1
mg/dl 1.1
Plasma phosphorus 10.0
mg/dl 2.9
Plasma creatinine 0. 13
mg/dl 0.07
Creatinine clearance 3.80
mi/mm 0.33
Urine calcium 0.52
mg/mg creatinine/24 hr 0.35
Urine phosphorus 2.62
mg/mg creatinine/24 hr 0.84
Urine hydroxyproline 89.8
pg/mg creatinmne/24 hrs 8.7
a Values are the mean one so
b All probabilities determined by the 1-test for unpaired samples
Probabilities determined by analysis of variance with contrasts except as indicated
d P < 0.01 vs. TPTX-C by non-paired 1-test
P < 0.001 vs. TPTX-C by non-paired 1-test
1P <0.01 vs. C by analysis of variance
g P < 0.01 vs. TPTX-C by analysis of variance
TPTX-AN 8
7.43 7.39 7.24
0.04 0.133 0.10
37.2 40.6 573f,g
3.8 3.2 10.8
21.2 23.7 l4.4f
2.4 2.3 3.9
7.8 4.sf 59f,g
0.5 0.6 1.3
6.5 1o.6f 82f,g
1.1 0.8 1.3
0.32
0.09
4.30
1.20
130"
0.83
3.08
of the two labels; the results are expressed in zm/day [18, 19].
The rate of bone formation at the epiphysis was determined by
multiplying the rate of bone apposition by the length of
trabecular bone surface that exhibited double tetracycline la-
bels. The results are expressed per unit area of trabecular bone
in mm2/mm2/day [18, 21].
Biochemical measurements—Experiments #1 and #2
The concentrations of calcium in plasma and urine were
determined by atomic absorption spcctroscopy [22]. Plasma
and urine phosphorus concentrations were measured using a
microcolorimetric method [23], and plasma and urine creatinine
concentrations were determined using the modified method of
Jaffe (Creatinine 11 Analyzer, Beckman Instruments, Fullerton,
California, USA) 1241. The concentrations of hydroxyproline in
urinc were determined by an automated modification of the
method of Kivirikko [25, 26], and serum 1,25 dihydroxyvitamin
D levels were measured using the cytoreceptor assay of Rein-
hardt ct al [27]. The limit of detection for 1,25 dihydroxyvitamin
D in serum using this assay is 4 pg per assay tube or 10 to 12
pg/mI [27].
Statistical analysis
All values are expressed as the mean one standard devia-
tion. Statistical analysis of the data was done using the 1-test for
unpaired samples, one—way analysis of variance with contrasts,
and linear regression analysis [28]. The values for plasma pH
were converted to hydrogen ion (H+) concentration, in
nEq/liter, for statistical evaluation.
Results
Plasma and urine biochemistries—Experiments #1 and #2
The values for plasma pH, hydrogen ion concentration, and
plasma bicarbonate were similar in Experiment #1 and Exper-
iment #2 for both TPTX control rats and TPTX acidotic
animals (Table 1). Plasma calcium concentrations were lower in
both groups of TPTX rats than in C in Experiment #2, but
plasma calcium concentrations increased in TPTX acidotic rats
when compared to TPTX-C in both studies (Table 1). The
values for plasma phosphorus were greater than in intact
controls (C) in each group of TPTX animals in Experiment #2
(Table 1). However, plasma phosphorus levels were reduced in
TPTX-A when compared to TPTX-C (Table I).
The serum levels of 1,25 dihydroxyvitamin D were at or
below the limit of detection by the assay in both TPTX-C and
TPTX-A in Experiment #2. Eight of nine rats in TPTX-C and
seven of eight animals in TPTX-A had concentrations of 1,25
dihydroxyvitamin D in serum that were at or below the detec-
tion limits of the assay. Thus, no detectable increase in serum
1,25 dihydroxyvitamin D levels was observed in TPTX-A in
Experiment #2.
The urinary excretion of hydroxyproline increased by 65% in
TPTX-A from the values determined in TPTX-C in Experiment
#1 (Table 1). Urinary calcium excretion was also greater in
TPTX acidotic animals than in TPTX-C in each experiment.
The excretion of phosphorus in the urine increased in TPTX-A
from the values in TPTX-C in Experiment #1, but the results
for urinary phosphorus excretion were not different between
Experiment #lb
TPTX-AN 10 CN = 10
Experiment #2C
TPTX-C
N= 9
7.19
0.03
64.6c
3.3
13 .9
1.8
6.4"
0.9
7.9
1.5
0.10
0.01
3.24"
0.43
1 .86c
0.79
5.9 I
0.97
150.2"
25.9
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Fig. 1. The rates of bone formation in pair—fed non-TPTX control,
TPTX control, and TPTX acidotic rats at the proximal tibial epiphysis
and at the tibial diaphysis. Bone formation was measured during a 14
day period using double tetracycline labeling. Symbols are: , P < 0.01
vs. non-TPTX-C; °', P < 0.01 vs. TPTX-C by analysis of variance; t P
<0.05 vs. TPTX-C by unpaired 1-test.
groups in Experiment #2 (Table 1). Weight gains during the
experiment were 22.7 7.7 g in C, 23.8 8.5 gin TPTX-C, and
14.0 19.7 g in TPTX-A, and these values did not differ among
groups.
Bone formation—Experiment #2
The rate of bone formation and the rate of mineralized bone
apposition were each diminished in TPTX-C when compared to
C at both the tibia! cortex and the proximal tibial epiphysis
(Figs. 1 and 2). These findings are consistent with the state of
hypoparathyroidism and hypocalcemia in TPTX control ani-
mals. In TPTX-A, the rates of bone formation and mineralized
bone apposition were further reduced from the values deter-
mined in TPTX-C at each of these two skeletal sites (Figs. 1 and
2). Thus, the lowest values for bone formation and for bone
apposition among the three study groups were observed in
TPTX-A. The extent of double tetracycline labeling at the
surface of bone was not different in TPTX-C and TPTX-A at
either the endosteal surface of the tibial cortex or the proximal
tibial epiphysis (Table 2).
Due to the high rate of bone turnover at the proximal tibia!
metaphysis, the fourteen day interval between doses of tetra-
cycline was too great to achieve double tetracycline labeling of
metaphyseal bone. Thus, the rates of bone formation and
mineralized bone apposition could not be determined at this
site, and only static histologic variables are presented for
metaphyseal bone.
Bone resorption—Experiment #2
The percent resorption surface at the epiphysis increased
from 1.80 0.58% in TPTX-C to 3.99 1.60% in TPTX-A (Fig.
3). Moreover, the values for percent resorption surface in
TPTX acidotic animals were similar to those for control rats
Fig. 2. The rates of mineralized bone apposition in pair—fed non-TPTX
control, TPTX control, and TPTX acidotic rats at the proximal tibial
epiphysis and at the tibial diaphysis. Symbols are: , P < 0.01 vs.
non-TPTX-C by analysis of variance; f, P < 0.05 vs. TPTX-C by
unpaired f-test.
Bone mineralization—Experiment #2
No evidence of osteoid accumulation was noted in animals
given ammonium chloride at any of the three skeletal sites
evaluated (Table 2). Although the width of osteoid seams at the
periosteal surface in cortical bone was greater in TPTX-C than
in C, this finding is consistent with data previously reported in
thyroparathyroidectomized rats. The values for periosteal
osteoid width were not different in TPTX-A and C (Table 2).
The widths of osteoid seams at the metaphysis and at the
epiphysis were also similar for each group, and there was no
difference between TPTX-C and TPTX-A in the values for total
osteoid area at either of these two skeletal sites (Table 2).
Discussion
The results of the current study indicate that metabolic
acidosis of two weeks duration in the rat is associated with
histologic and biochemical evidence of increased bone resorp-
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with intact parathyroid glands, 3.15 1.14%. Despite these
changes, total bone area at the tibial epiphysis did not differ
among C, TPTX-C, and TPTX-A (Table 2).
In contrast, the percent resorption surface in both cortical
bone and metaphyseal bone was similar among the three study
groups (Fig. 3); specifically, resorption surface did not increase
in acidotic animals from the values determined in either control
group. Total bone area at the tibial cortex was also similar in
each group, and there was no evidence of a decrease in cortical
bone thickness or in cortical bone area in TPTX-A (Table 2).
However, the total bone area at the proximal tibial metaphysis
was reduced in TPTX-A when compared to both C and TPTX-C
(Table 2).
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Table 2. Bone histology at three skeletal sites in control (C), thyroparathyroidectomized control (TPTX-C), and thyroparathyroidectomized
acidotic (TPTX-A) rats'"
Tibial epiphysis Tibial metaphysis Tibial cortex
non-TPTX TPTX TPTX non-TPTX TPTX TPTX non-TPTX TPTX TPTXC C A C C A C C AN=l0 N=9 N=8 N=10 N=9 N=8 N=lO N=9 N=8
Bone area 15,8 16.1 13.2 12.8 15.5 9.0c 63.1 59.7 59,9% of tissue area 1.8 2.3 4,7 4.9 5.6 4.3 3.1 4.0 3,9Osteoid area 1.9 1.1 0,5d 4.4 2.0 1.9 2.7 4.Oe 33c,d% of bone area 1.1 0.7 0.6 3.4 1.4 1.4 0.4 0.6 0.5Osteoid seam width 3.3 3.8 3.3 3.5 3.5 3.8 6.9 9,3C 741jim ±0.9 ±0.7 ±L7 ±1.2 ±1.3 ±0.7 ±0.8 ±1.0 ±1.4Osteoid surface' 11.2 7.1 4.6 11.9 8.9 9.8 61.1 63.0 70.6% of bone surface ± 9.7 ± 4.3 ± 4.4 ± 5.2 ± 4.0 ± 4.6 ±14.4 ±18.6 ±11.1
Resorption surface 3.1 18g 4,0 6.0 6.8 5.9 38.9 37.0 29.4
% of bone surface ± 1.1 ± 0.6 ± 1.6 ± 3.1 ± 5.5 ± 3.1 ±14.4 ±18.6 ±11.1
Double tetracyclin&' 13.8 9.6 4,9(1 — 61.1 63.0 70.6labeled surface ± 6.2 ± 4.4 ± 4.6 ±14.4 ±18.6 ±11.1
% of bone surface
a Values are the mean ± one so
b Probabilities determined by analysis of variance with contrasts except as indicated
P < 0.05 vs. TPTX-C
P < 0.05 vs. C
P C 0.01 vs. C
C 0.01 vs. TPTX-C
g P C 0.05 vs. C by non-paired t-test
As determined at endosteal surfaces in cortical bone
tion in TPTX animals. Bone formation was also substantially
diminished from control values in TPTX acidotic rats. Concur-
rent with these changes, the volume of bone was reduced in the
metaphysis of the proximal tibia. In spite of marked impair-
ments in the rate of new bone formation, no histologic evidence
of defective mineralization was found. The data suggest that
both reductions in the formation of bone and increases in bone
resorption contribute to the development of osteopenia in
metabolic acidosis, and that these changes are not mediated by
alterations in the secretion of parathyroid hormone (PTH).
Histologic findings consistent with enhanced cell—mediated
bone resorption were noted in the epiphysis of the proximal
tibia. Increases in bone resorption surface have also been noted
in microradiographic studies of cortical bone from the femur in
acidotic rats with intact parathyroid glands [41. Furthermore,
Delling and Donath reported morphologic changes in osteo-
clasts that suggested an increase in cellular activity in both
TPTX and non-TPTX acidotic rats [9]. In conjunction with the
histologic results of the current studies, the urinary excretion of
hydroxyproline increased in TPTX acidotic animals, and cal-
cium excretion in the urine also rose during metabolic acidosis.
Similar changes in urinary hydroxyproline excretion were re-
ported by Goulding and Campbell [29] and by Cuisinier—Glizes,
Mathieu and Royer (30) in thyroparathyroideetomized rats with
metabolic acidosis induced by ammonium chloride feeding.
Thus, both the histologic and biochemical findings of the
current and other investigations provide evidence in support of
enhanced bone resorption in acidotic animals.
In contrast to the increase in resorption surface noted in the
epiphysis, resorption surface was not altered during metabolic
acidosis in either cortical or metaphyseal bone, and these
results differ from data previously reported by Barzel and
Jowsey in rat cortical bone [4]. The present study was done in
TPTX animals, and metabolic acidosis has been shown to
40.0
35.0
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30.0
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Ca CC
C C.-C 10.0
7,5
5.0
25
NON-TPTX TPTX
TPTX
Tihial Tibial Tibial
epiphysis metaphysis diaphysis
Fig. 3. The extent of resorption surface at three skeletal sites in
non-TPTX control, TPTX control, and TPTX acidotic rats. Resorption
surface is expressed as the percentage of the total bone surface for each
site; the values for cortical bone represent measurements at the
endosteal surface. Symbols are: ', P C 0.01 vs. non-TP'FX-C; P C
0.05 vs. TPTX-C by analysis of variance.
increase the secretion of PTH and to enhance the biological
effects of PTH on bone [31, 32]. In the current study, it is likely
that the stimulation of cell—mediated bone resorption during
metabolic acidosis was blunted in the absence of PTH. Also,
the duration of metabolic acidosis was greater than 300 days in
the study of Barzel and Jowsey [4], whereas the current
experimental results were obtained after only 14 days of
acid—feeding. This shorter time interval may have been insuffi-
cient to maximally stimulate the resorption of bone in the tibial
NON-TPTX TPTX NON-TPTX TPTX
TPTX TPTXCC A C C A CC A
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cortex. These findings do suggest, however, that trabecular
bone in the tibial epiphysis is more sensitive than cortical bone
to the stimulation of cell—mediated bone resorption by meta-
bolic acidosis. It is possible that skeletal sites which undergo
secondary remodeling respond differently to metabolic acidosis
than regions of the skeleton engaged in primary bone modeling
[33]. This issue will require additional study. However, the
current experimental observations are consistent with recent
data which indicate that the response of bone to several
hormonal and chemical stimuli may differ at various sites within
the skeleton [14—16].
The mechanism responsible for the increase in bone resorp-
tion at the tibial epiphysis in acidotic animals is not apparent
from the current experimental data. Results from in vitro
studies indicate that calcium is released from devitalized bone
when the pH of the medium is reduced, but that cell—mediated
bone resorption is not stimulated by modifications in media pH
within the physiologic range [5, 7]. Thus, rather than a direct
effect of pH, humoral or biochemical changes that occur with
metabolic acidosis in vivo may be responsible for the increase
in cell—mediated bone resorption reported herein. By design,
the levels of PTH in serum were low in acidotic animals.
Although the serum concentrations of 1,25 dihydroxyvitamin D
were at the lower limit of detection by the assay employed,
there were no detectable increases in the serum levels of 1,25
dihydroxyvitamin D in acidotic animals. However, the concen-
trations of phosphorus in serum were lower in TPTX acidotic
rats than in TPTX controls. Reductions in serum phosphorus
levels are associated with high rates of bone resorption in the
rat, but such changes have been reported in animals with overt
phosphorus depletion and hypophosphatemia [34]. Neither of
these findings was present in TPTX acidotic rats. It remains
uncertain, therefore, whether the modest decrement in serum
phosphorus concentration that occurred with acidosis in the
current study is sufficient to explain the histologic findings in
epiphyseal bone. If so, the increase in bone resorption in
acidotic animals was mediated directly by the fall in serum
phosphorus level and not by measureable phosphate—mediated
increases in the serum concentrations of 1,25 dihydroxyvitamin
D.
Bone formation was substantially reduced at all skeletal sites
as determined using double tetracycline labeling. This finding is
in contrast to the data of Barzel and Jowsey [4] who reported
that metabolic acidosis did not affect bone formation. However,
bone formation in this earlier study was assessed by microradi-
ographic analyses of the extent of osteoid surfaces in rat
cortical bone [4]. Because tetracycline—based measurements of
bone dynamics evaluate both the extent of bone forming surface
and the formation activity of osteoblasts along that surface, the
use of double tetracycline labeling provides a more precise
index of the rate of bone formation. Indeed, the current results
are consistent with the data of Barzel and Jowsey with regard to
the extent of osteoid surfaces at each skeletal site [4]; these
values were not different in control and acidotic rats.
Both caloric intake and the rate of weight gain were low in all
three study groups in Experiment #2, and these changes may
impair bone formation [35, 36]. However, total weight gains
were not different among groups. Thus, the reductions in bone
formation in TPTX acidotic animals appear to be the conse-
quence of the acidotic state. Whether this difference represents
a direct adverse effect of acidemia on the function of the
osteoblasts or whether it is mediated by reductions in the level
of phosphorus in serum remains to be determined.
Despite substantial reductions in the rate of bone formation,
bone that formed during the period of acidemia mineralized
normally as judged by histologic criteria. No evidence of
osteoid accumulation or of defective mineralization was found
in acidotic animals. These data using tetracycline—based mea-
surements are consistent with previous morphologic studies of
bone in experimental animals with metabolic acidosis [4].
Although TPTX rats were examined in the current study,
previous investigations in rats with intact parathyroid glands
have also failed to document changes of osteomalacia [4].
Osteomalacia is not infrequently observed in humans with
metabolic acidosis, particularly children with renal tubular
acidosis [11—13, 37]. This finding was initially attributed to
reductions in the serum levels of 1,25 dihyroxyvitamin D [38],
but several groups of investigators have reported that the levels
of 1,25 dihydroxyvitamin D in serum are not low in humans
with metabolic acidosis [39—41]. In contrast, reductions in the
concentration of 1,25 dihydroxyvitamin D in serum have been
documented in some studies of acidotic rats [42]. Based upon
these observations, it is unlikely that the occurrence of osteo-
malacia in humans with metabolic acidosis is due primarily to
alterations in the production of 1,25 dihydroxyvitamin D as
described in the rat. Moreover, the reductions in serum 1,25
dihydroxyvitamin D levels in acidotic rats are not associated
with substantial disturbances in the mineralization of bone as
judged by histologic techniques [4]. However, hypophosphate-
mia is often present in non-uremic patients with chronic meta-
bolic acidosis and osteomalacia [11—13], and the resolution of
skeletal lesions of osteomalacia during alkalai therapy is asso-
ciated with marked improvements in phosphorus balance [11,
12]. Thus, alterations in the metabolism of phosphorus during
acidosis may be an important determinant in the development
of osteomalacia in humans with metabolic acidosis.
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